Ecuador vs Mus: HIV-positive TB patients on ART (antiretroviral therapy)
Ecuador
100.0%
in 2024
Mus
100.0%
in 2024
Ecuador rank
1st
Mus rank
1st
HIV-positive TB patients on ART (antiretroviral therapy) over time
- Ecuador
- Mus
How they compare
Ecuador currently reports 100.0% against 100.0% in Mus, a difference of 0.0%.
The two have swapped places 5 times across 17 shared years of data; in 2007 it was Ecuador ahead.
Ecuador ranks 1st and Mus ranks 1st of 144 countries.
Across the 3 decades both report, Ecuador averaged higher in 2 and Mus in 1.
Head to head by decade
| Decade | Ecuador | Mus | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 100.0% | 69.0% | 31.0% | Ecuador |
| 2010s | 95.8% | 88.9% | 6.9% | Ecuador |
| 2020s | 93.8% | 100.0% | 6.2% | Mus |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv-positive tb patients on art (antiretroviral therapy), Ecuador or Mus?
- Ecuador, at 100.0% against 100.0% in Mus as of 2024.
- What is the difference in hiv-positive tb patients on art (antiretroviral therapy) between Ecuador and Mus?
- 0.0%, with Ecuador ahead.
- How many years of comparable data are there for Ecuador and Mus?
- 17 years are reported by both, from 2007 to 2024.
- How do Ecuador and Mus rank globally for hiv-positive tb patients on art (antiretroviral therapy)?
- Ecuador ranks 1st and Mus ranks 1st of 144 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as HIV-positive TB patients on ART (antiretroviral therapy) (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.